VYZULTA: payments to doctors
Payments that named VYZULTA as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $6.8M
- Providers
- 17,680
- Transactions
- 73,942
- Average per transaction
- $92
The per-transaction average — $92 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 17,680 providers the average total is $383, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Bausch & Lomb Americas Inc. | $3,949,322 | 58.3% |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | $2,819,288 | 41.6% |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | $2,000 | 0.0% |